Thrombin generation assay
- 1 December 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 23 (8), 680-687
- https://doi.org/10.1097/mbc.0b013e328355111f
Abstract
Antithrombotic therapy (including antiplatelet and anticoagulant drugs) is the cornerstone of the current medical treatment of patients with acute coronary syndromes (ACS). This therapy and particularly the new antiplatelet and anticoagulant drugs have significantly reduced the ischemic risk, but have increased bleeding complications. Recently, several studies have emphasized the negative prognostic impact on long-term mortality of these bleeding adverse events. Thus, new assays to estimate the bleeding risk and the efficacy of these antithrombotic drugs are clearly in demand. Regarding the anticoagulant drugs, new promising data have emerged about the thrombin generation assay (TGA). TGA measures the ability of plasma to generate thrombin. TGA may be used to check coagulation function, to value risk of thrombosis and to compare the efficacy of different anticoagulants employed in clinical management of patients with ACS. The TGA result is a curve which describes the variation of thrombin's amount during the activation of the coagulation cascade. All available anticoagulant drugs influence the principal parameters generated by TGA and so it is possible to evaluate the effects of the medical treatment. In this review we provide a brief description of the assay and we summarize the principals of previous studies by analyzing the relationship between anticoagulant drugs and TGA. Moreover, a brief summary of its ability to predict ischemic and bleeding risks has been provided. Blood Coagul Fibrinolysis 23: 680-687 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.Keywords
This publication has 27 references indexed in Scilit:
- Anticoagulants and the Propagation Phase of Thrombin GenerationPLOS ONE, 2011
- In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinuxThrombosis Research, 2011
- Composition of Coronary Thrombus in Acute Myocardial InfarctionJournal of the American College of Cardiology, 2011
- Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin‐activatable fibrinolysis inhibitorJournal of Thrombosis and Haemostasis, 2010
- Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?Pharmacological Research, 2009
- Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor compositionJournal of Thrombosis and Haemostasis, 2008
- Thrombin Generation Assay and Viscoelastic Coagulation Monitors Demonstrate Differences in the Mode of Thrombin Inhibition Between Unfractionated Heparin and BivalirudinAnesthesia & Analgesia, 2007
- New anticoagulantsBlood, 2005
- Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarctionBritish Journal of Haematology, 2004
- Increased levels of soluble tissue factor during long‐term treatment with warfarin in patients after an acute myocardial infarctionJournal of Thrombosis and Haemostasis, 2004